Algorae Pharmaceuticals Limited has released a press release.
Preliminary Final Report and Financial Statements
Filed with ASX ·
6ix hasn’t read this filing yet.
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- NTCELL continues to halt progression of Parkinsons disease
- LCT collaborates with CBR to extend product pipeline
- Treatment completed for all patients in Parkinsons trial
- Living Insights Newsletter February 2017
- Approval granted for group 3 in Parkinsons trial
Later from Algorae Pharmaceuticals
- Appendix 4C Quarterly Cash Flow Report 30 September 2017
- LCT files pericyte protective agent provisional patent
- Results of LCT Parkinsons trial require further analysis
- Appendix 4C - Quarterly
- LCT to sell JV Shares and receive DIABECELL licence
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals